IPO fever is back in full force with the public announcement of Twitter's IPO plans to raise up to $1 billion.
Twitter's site was flooded shortly after 5 p.m. Thursday with tweets about the company's IPO filing.
It's the first step to figuring out if Twitter is a buy...
With the wheels set in motion for a Twitter stock IPO, the inevitable comparisons to Facebook Inc. (Nasdaq: FB) and its disastrous IPO have already started.
But apart from the fact that both are social media stocks, the Twitter stock IPO – which is on track to start trading sometime in November – does not figure to have a lot in common with the Facebook IPO.
Chrysler LLC has filed for an initial public offering (IPO), returning to publicly traded status after 15 years in the wilderness of global business uncertainty – and the Chrysler IPO comes at a great time for the company and for the whole American auto industry.
You see, not even five years ago, the Big Three were teetering on the edge of destruction and irrelevance, with dismal sales and empty coffers, running losses in the hundreds of millions on products that nobody wanted. The global financial crisis was the last nail in a coffin more than 10 years in the crafting.
To continue reading, please click here...
The Twitter stock IPO is going to happen – it's no longer a question of if, but of when. The company is the latest social media concern to go public, and investors and commentators alike are looking forward to the festivities.
It remains to be seen whether or not NASDAQ can avoid the issues that it ran into with Facebook Inc. (Nasdaq: FB). That IPO was one of the biggest in history. The company had a market cap of $104 billion, unprecedented for an IPO.
To continue reading, please click here...
It's been a busy year for initial public offering (IPO) investing, and despite recent volatility, it's looking to be a busy fall for the new issues market…
The stock market has remained firm in spite of increasing tensions in the Middle East and the fear of quantitative easing (QE) tapering from the U.S. Federal Reserve.
To continue reading, please click here...
The IPO market has had a strong first half in 2013, in some cases delivering double-digit gains for those who have ventured into IPO investing.
As the stock market has staged an impressive rally, investor demand to get into the IPO market is returning to pre- credit-crisis levels. The second quarter was actually the most active three-month period for IPOs in six years.
So far in 2013, we have seen 92 deals. The average gain for initial buyers is around 20%.
The pace seems to be picking up, as the first quarter saw 31 deals raise about $7.6 billion, and the second quarter had 61 offerings raise more than $13 billion.
Financial firms, including real estate investment trusts (REITs), have been the most active industry, with 35 offerings. Healthcare companies are right behind, closing in on 34 deals so far this year.
Some analysts think we could see more than 200 deals by the end of the year.
That means more opportunity for IPO investing for double-digit gains…here's where to look.
To continue reading, please click here...
Money Morning Chief Investment Strategist Keith Fitz-Gerald holds forth on FOX Business' "Varney & Co." about the biggest topics today, including the war of words between Kris Jenner and President Obama, and what he thinks of a market that's too hung up on Ben Bernanke.
Later, Keith is asked about the hotly-rumored Twitter IPO: What does Keith think of the social media giant's possible move into the market? Who makes money on these IPOS?
Each of the companies you'll see today is just a few weeks old. That's why you need to know about them right now.
You see, the market for all biotech shares is heating up.
IPO action is proof of the big bucks coming into biotech, igniting a strong rally in the entire sector for the rest of the year. So far this year, we've seen the most biotech IPOs in 13 years.
And the gains are beginning to add up…
The best-performing stock in this space, as you're about to see, is up 130% in little more than a month. And three other brand-new firms are roaring.
But there's a better way to make money here…
I'm astounded by the success of biotech IPOs that have been rolling into the markets in recent weeks. These companies are teaming up with bigger pharma companies, which guarantees the capital and distribution heft for their new innovative drugs.
